However, our panel included additional conditions such as tyrosinemias (TYR1–3), other fatty acid oxidation disorders (e.g., VLCAD, SCAD, PCD), and further subtypes of galactosemia (GALK deficiency), which likely contribute to the higher total number of screened disorders. The gene discussed is GALK1; the disease is classic galactosemia.